PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-articular Injections of Spryng™ with OsteoCushion™ Technolgoy
- None.
- None.
Insights
The release of clinical study results for PetVivo Holdings' Spryng with OsteoCushion Technology represents a significant development in the field of veterinary medicine, specifically in the treatment of joint-related conditions in companion animals. The study's focus on the intra-articular injections of collagen-elastin hydrogel microparticulates into feline joints is a novel approach to managing conditions such as osteoarthritis, which is prevalent in the aging pet population. The safety profile, as indicated by the similarity of post-injection outcomes to a benign control, is a critical factor for veterinarians and pet owners when considering treatment options.
From a business perspective, the positive safety results could lead to increased adoption of Spryng in veterinary practices, potentially driving revenue growth for PetVivo Holdings. The company's ability to demonstrate safety and efficacy through independent research could also enhance its credibility and market position. However, it is essential to consider the scalability of production and distribution networks to meet potential demand increases, as well as the competitive landscape of alternative treatments for joint afflictions in animals.
Understanding the impact of PetVivo's clinical study results on the stock market requires an analysis of investor sentiment and market trends. The pet care industry has been growing steadily, supported by the humanization of pets and increased spending on pet health. Innovative treatments like Spryng could capture a significant market share if proven effective and safe. The study's outcome may attract investor attention, potentially influencing PetVivo's stock valuation.
However, it is important to monitor the company's marketing strategy and distribution channels to ensure the product reaches its target market effectively. Additionally, regulatory hurdles and the speed of commercialization will play a role in the financial performance of PetVivo. Investors will be looking for signs of strategic partnerships, potential for market expansion and sustained R&D efforts to gauge long-term growth prospects.
The financial implications of the clinical study results for PetVivo Holdings are multifaceted. On one hand, the safety of Spryng could lead to increased sales and market penetration, contributing positively to the company's bottom line. On the other hand, the costs associated with the development, marketing and potential post-market surveillance of the product must be scrutinized. It is essential to evaluate the company's current financial health, cash flow and investment in continued research and development to ensure long-term viability.
Investors will also assess the potential return on investment, considering the size of the companion animal joint health market and the product's pricing strategy. It is crucial to analyze the company's financial statements and forecasts in light of this new development to understand its impact on profitability and shareholder value. Furthermore, the company's response to competitive pressures and its ability to secure intellectual property rights will influence its financial outlook.
MINNEAPOLIS, MN, US, Feb. 07, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that the Company has released the results of a clinical study conducted by Inotiv, Inc., a world-renowned independent clinical research organization, which examined the safety of intra-articular injections of collagen-elastin hydrogel microparticulates (i.e. Spryng™ with OsteoCushion™ Technology) into the joints of cats.
“We are pleased to have the release of the final results of this Spryng tolerance study as this data demonstrates the safety of our veterinary medical device, Spryng, when injected into the joints of cats,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We continue to strive to provide data demonstrating that Spryng is a viable tool to use in the management of joint related afflictions found in companion animals, such as cats.”
SPRYNG with OsteoCushion Technology is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
The data provided demonstrated the excellent safety profile of Spryng when injected IA into 40 joints (10 each, shoulder, hip, elbow, stifle) across 10 individual cats. Use of Spryng was similar to a benign control (saline) in regard to incidences of lameness, joint swelling, or pain after IA injection, and post-injection outcomes were most often no different than pre-injection baseline measures.To view the Technical Bulleton discussing the tolerability study involving the intra-articular injection of Spryng in the joints of cats, please visit the following:
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/ or http://sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is the name of the company mentioned in the press release?
What is the ticker symbol for PetVivo Holdings, Inc.?
What is the name of the clinical research organization that conducted the study?
What is the name of the veterinary medical device mentioned in the press release?
What were the results of the clinical study regarding the safety of Spryng?
